Beta

Tyra biosciences, inc.TYRA.US Overview

US StockHealthcare
(No presentation for TYRA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

TYRA AI Insights

TYRA Overall Performance

TYRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TYRA Recent Performance

-2.26%

Tyra biosciences, inc.

0.93%

Avg of Sector

0.67%

S&P500

TYRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check TYRA's Trend

TYRA Key Information

TYRA Valuation Metrics

TYRA Profile

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Price of TYRA

TYRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TYRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.63
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.63
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TYRA's latest earnings report released?

    The most recent financial report for Tyra biosciences, inc. (TYRA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TYRA's short-term business performance and financial health. For the latest updates on TYRA's earnings releases, visit this page regularly.

  • How much debt does TYRA have?

    As of the end of the reporting period, Tyra biosciences, inc. (TYRA) had total debt of 5.81M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TYRA have?

    At the end of the period, Tyra biosciences, inc. (TYRA) held Total Cash and Cash Equivalents of 78.39M, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TYRA's EPS continuing to grow?

    According to the past four quarterly reports, Tyra biosciences, inc. (TYRA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.56. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TYRA?

    Tyra biosciences, inc. (TYRA)'s Free Cash Flow (FCF) for the period is -23.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 20.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TYRA?

    The latest valuation data shows Tyra biosciences, inc. (TYRA) has a Price-To-Earnings (PE) ratio of -14.6 and a Price/Earnings-To-Growth (PEG) ratio of -0.83. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.